In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Caribou Biosciences, with a price target of $9.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Robert Burns has given his Buy rating due to a combination of factors, including Caribou Biosciences’ promising financial position and the positive clinical trial results of their CB-010 product. The company’s financials for the third quarter of 2025 showed a net loss per share that was better than previously estimated, and their cash reserves are projected to sustain operations into the second half of 2027.
Furthermore, the clinical data from the ANTLER trial for vispa-cel (CB-010) demonstrated efficacy results comparable to FDA-approved CAR-T therapies, with notable improvements in safety profiles. The initiation of a Phase 3 trial, backed by the FDA’s recommendation, highlights the potential of their optimized vispa-cel product to become a preferred treatment option. These factors collectively support the Buy rating and a 12-month target price of $9 per share.
In another report released on November 13, Truist Financial also reiterated a Buy rating on the stock with a $7.00 price target.